The FDA had promised to render a decision on the approval of aducanumab by March 7. The process is now being extended to June 7.
FDA delays approval decision for Biogen’s Alzheimer’s treatment
Posted in biotech/medical, neuroscience
Posted in biotech/medical, neuroscience
The FDA had promised to render a decision on the approval of aducanumab by March 7. The process is now being extended to June 7.